



## Deprescribing of Problematic Polypharmacy

Guest Editor:

**Dr. Duncan Petty**

School of Pharmacy, University of  
Bradford, Bradford, England, UK

Deadline for manuscript  
submissions:

**closed (15 August 2019)**

### Message from the Guest Editor

The population of most countries is getting older and patients now commonly live with multimorbidity, which in turn is treated with increasing amounts of repeat prescriptions (polypharmacy). In addition, the increase in polypharmacy for older people is also fueled by the perceived need of prescribers to follow national guidance which encourage prescribing. Whilst prescribing may have benefits that outweigh risks, as patients become older and frailer it may be that some prescribing is no longer appropriate. As a consequence, health commissioners, practitioners and researchers are encouraging a focus on deprescribing of medicines that are no longer suitable, unlikely to provide benefit or are causing, or could cause, more harm than benefit.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Jon Schommer

College of Pharmacy, University  
of Minnesota, Minneapolis, MN  
55455, USA

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Pharmacy* (ISSN 2226-4787). *Pharmacy*, an international scientific open access journal on pharmacy education and practice, is published by MDPI online quarterly. *Pharmacy* is published in open access format—research articles, reviews and other contents are released on the Internet immediately after acceptance.

The scientific community and the general public have unlimited and free access to the content as soon as it is published.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within ESCI (Web of Science), PubMed, PMC, Embase, and other databases.

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.9 days after submission; acceptance to publication is undertaken in 3.7 days (median values for papers published in this journal in the first half of 2024).

## Contact Us

---

Pharmacy Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmacy](http://mdpi.com/journal/pharmacy)  
[pharmacy@mdpi.com](mailto:pharmacy@mdpi.com)  
[X@Pharmacy\\_MDPI](https://twitter.com/Pharmacy_MDPI)